Trials / Completed
CompletedNCT01777529
Comparative Study of the Immunogenicity of MMR (Measles, Mumps and Rubella) Single Dose and Multidose Presentations
Comparative Study of the Immunogenicity of MMR (Measles, Mumps and Rubella), Single Dose and Multidose Presentations in Children 12 to 23 Months of Age.
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 240 (actual)
- Sponsor
- The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz) · Academic / Other
- Sex
- All
- Age
- 12 Months – 23 Months
- Healthy volunteers
- Accepted
Summary
Whether the lower immunogenicity of the mumps component obtained in clinical studies with the MMR in Brazil, due to the multidose presentation. Investigations were made on factors that could interfere with immunogenicity of mumps component, as the kits used for the immunoassay method, and potency of the vaccine, but no explanation was found. This study aimed to investigate the hypothesis that the lower immunogenicity of the mumps component of the MMR Bio-Manguinhos vaccine, is due to the multidose presentation. The Main objetctive is evaluate the immunogenicity of MMR after one dose in children 12 to 23 months of life, comparing the performances multidose vial (10 doses per vial of vaccine produced in Bio-Manguinhos/Fiocruz through technology transfer from GlaxoSmithKline Laboratory - GSK) and single dose vial (1 dose per vial of vaccine produced by GSK).
Detailed description
Study Design This is a clinical trial Phase IV, randomized, single-blind, with two arms: * MMR (TV) combined measles, mumps and rubella vaccine produced in Bio-Manguinhos, applied to healthy children 12 to 23 months. Multidose presentation, only from one batch. * MMR (GSK-TV), produced by GlaxoSmithKline, the same age. Monodose presentation, only from one batch. Locations of the study * CMS Heitor Beltrão - Tijuca * CMS Milton Fontess Magarão - Engenho de Dentro * CMS Waldyr Franco - Bangu
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | MMR Vaccine | Administration of MMR Vaccine by Bio-Manguinhos or MMR Vaccine by GlaxoSmithKline |
Timeline
- Start date
- 2012-10-01
- Primary completion
- 2013-01-01
- Completion
- 2013-12-01
- First posted
- 2013-01-29
- Last updated
- 2016-07-11
Locations
1 site across 1 country: Brazil
Source: ClinicalTrials.gov record NCT01777529. Inclusion in this directory is not an endorsement.